FCGR3A and neoplasm: This can be accomplished either by improving CD16 interaction with mAbs or by combining tumor-targeting mAbs with agents capable of acting on stimulatory receptors and/or interfering with inhibitory signals that characterize the immunosuppressive TME or by optimizing NK cell survival/proliferation, recruitment, and persistence in tumor sites.